Clinical Potential of Tissue Tumor Mutational Burden (tTMB) and Blood TMB (bTMB) as a Biomarker in Non-Small Cell Lung Cancer

被引：0
|
作者：
Zhou, J. [1 ]
Zhou, J. [1 ]
Chen, X. [1 ]
Zhu, Y. [1 ]
Fang, L. [1 ]
Bao, Z. [1 ]
Liu, R. [1 ]
Cao, H. [1 ]
Sun, W. [1 ]
Zhang, T. [2 ]
Lin, J. [2 ]
Yu, B. [2 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Resp Dis, Thorac Dis Ctr,Coll Med, Hangzhou, Zhejiang, Peoples R China
[2] Burning Rock Biotech, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
tTMB; bTMB; NSCLC;
D O I：
10.1016/j.jtho.2019.08.751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-36
引用
收藏
页码：S370 / S370
页数：1
相关论文
共 50 条
  • [31] High Tumor Mutational Burden in Rare and Complex EGFR Mutant Non-Small Cell Lung Cancer
    Mo, A.
    Guha, C.
    Guha, U.
    Ohri, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E255 - E256
  • [32] Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view
    Penault-Llorca, Frederique
    Radosevic-Robin, Nina
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 716 - 721
  • [33] Tumor Mutational Burden as a Potential Predictive Biomarker of Response to PD-1/PD-L1 Blockade in Non-Small Cell Lung Cancer
    Kim, H.
    Kwon, H. J. K.
    Kim, E. S. K.
    Han, Y. B.
    Lee, J.
    Kim, S. H.
    Kim, Y. J.
    Lee, J.
    Chung, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S470 - S470
  • [34] Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782
    Bar, Jair
    Esteban, Emilio
    Rodriguez-Abreu, Delvys
    Aix, Santiago Ponce
    Szalai, Zsuzsanna
    Felip, Enriqueta
    Gottfried, Maya
    Provencio, Mariano
    Robinson, Andrew
    Fulop, Andrea
    Rao, Suman Bannur
    Camidge, D. Ross
    Speranza, Giovanna
    Townson, Steven M.
    Kobie, Julie
    Ayers, Mark
    Dettman, E. J.
    Hunkapiller, Nathan
    Mcdaniel, Robert
    Jung, Byoungsok
    Burkhardt, David
    Mauntz, Ruth
    Csoszi, Tibor
    LUNG CANCER, 2024, 190
  • [35] Mutational signatures in the perspective of tumour mutational burden in patients with non-small cell lung cancer
    Van den Heuvel, G.
    Kroeze, L.
    Ligtenberg, M.
    Grunberg, K.
    von Rhein, D.
    Jansen, E.
    de Voer, R.
    Van den Heuvel, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1217 - S1218
  • [36] Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer
    Sharpnack, Michael F.
    Cho, Ju Hwan
    Johnson, Travis S.
    Otterson, Gregory A.
    Shields, Peter G.
    Huang, Kun
    Carbone, David P.
    He, Kai
    LUNG CANCER, 2020, 146 : 36 - 41
  • [37] Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.
    Velcheti, Vamsidhar
    Kim, Edward S.
    Mekhail, Tarek
    Dakhil, Christopher
    Stella, Philip J.
    Shen, Xiaowei
    Hu, Sylvia
    Paul, Sarah M.
    Shames, David S.
    Yun, Cindy
    Phan, See-Chun
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Spotlight on tumor mutational burden in patients with non-small cell lung carcinoma Preface
    Ilie, Marius
    Hofman, Paul
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 614 - 615
  • [39] Uncommon EGFR mutations are associated with higher tumor mutation burden (TMB) in non-small cell lung cancer patients
    Shen, Xudong
    Zhang, Hushan
    Huang, Depei
    CANCER RESEARCH, 2020, 80 (16)
  • [40] Impact of intratumor heterogeneity (ITH) on survival outcomes in patients with non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB-H)
    Fridland, Stanislav
    Kim, Hye Sung
    Chae, Young Kwang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345